stockrowOruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Return on equity
Oruka Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −18.3%, up 6.6 percentage points from fiscal 2025 (−24.9%). Over the past ten years it has ranged from −113.9% (fiscal 2017) to −13.6% (fiscal 2023); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −24.9% | 15.36 |
| FY2024 | −40.2% | (26.65) |
| FY2023 | −13.6% | 7.84 |
| FY2022 | −21.4% | 18.20 |
| FY2021 | −39.6% | (3.63) |
| FY2020 | −36.0% | 44.39 |
| FY2019 | −80.4% | 16.93 |
| FY2018 | −97.3% | 16.59 |
| FY2017 | −113.9% | (59.32) |
| FY2016 | −54.6% | (11.23) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. | −18.3% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| AXSM Axsome Therapeutics, Inc. compare | −175.6% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)